Liraglutide

Generic Name
Liraglutide
Brand Names
Saxenda, Victoza, Xultophy
Drug Type
Biotech
Chemical Formula
-
CAS Number
204656-20-2
Unique Ingredient Identifier
839I73S42A
Background

Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.

Indication

Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years old who weigh ≥60 kg and have an initial BMI corresponding to obesity based on international cut-offs.

Victoza, a formulation of liraglutide used in diabetes, is indicated as an adjunct to diet and exercise to improve glycemic control in patients ≥10 years old with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease.

Liraglutide is also available in combination with insulin degludec as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.

Associated Conditions
Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
Associated Therapies
Chronic Weight Management therapy

Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

First Posted Date
2015-06-16
Last Posted Date
2017-07-17
Lead Sponsor
University Health Network, Toronto
Registration Number
NCT02472717
Locations
🇨🇦

Toronto Western Hospital, The Centre for Prognosis Studies in the Rheumatic Diseases (CPSRD), University of Toronto, Toronto, Ontario, Canada

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

First Posted Date
2015-06-03
Last Posted Date
2019-07-31
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
706
Registration Number
NCT02461589
Locations
🇬🇧

Novo Nordisk Investigational Site, Truro, United Kingdom

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

First Posted Date
2015-05-25
Last Posted Date
2020-04-17
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
957
Registration Number
NCT02453711
Locations
🇬🇧

Novo Nordisk Investigational Site, Rotherham, United Kingdom

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

First Posted Date
2015-05-13
Last Posted Date
2021-04-09
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
308
Registration Number
NCT02443155
Locations
🇬🇧

Novo Nordisk Investigational Site, Swansea, United Kingdom

Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects

First Posted Date
2015-04-03
Last Posted Date
2016-09-12
Lead Sponsor
Medical University of Graz
Target Recruit Count
14
Registration Number
NCT02408705
Locations
🇦🇹

Medical University Graz, Graz, Austria

The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-03-31
Last Posted Date
2024-07-22
Lead Sponsor
Phoenix VA Health Care System
Target Recruit Count
97
Registration Number
NCT02403284
Locations
🇺🇸

Carl T. Hayden VA Medical Hospital, Phoenix, Arizona, United States

The Lira Pump Trial

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-01-30
Last Posted Date
2020-02-12
Lead Sponsor
Hvidovre University Hospital
Target Recruit Count
44
Registration Number
NCT02351232
Locations
🇩🇰

Steno Diabetes Center, Gentofte, Denmark

🇩🇰

Hvidovre University Hospital, Hvidovre, Denmark

Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes

Phase 4
Conditions
Interventions
First Posted Date
2015-01-22
Last Posted Date
2022-07-29
Lead Sponsor
Temple University
Target Recruit Count
12
Registration Number
NCT02344186
Locations
🇺🇸

Temple University Hospital, Philadelphia, Pennsylvania, United States

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2014-12-24
Last Posted Date
2019-12-18
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
45
Registration Number
NCT02324842
Locations
🇺🇸

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

First Posted Date
2014-12-22
Last Posted Date
2017-09-01
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
1092
Registration Number
NCT02321878
Locations
🇯🇵

Novo Nordisk Investigational Site, Tokyo, Japan

© Copyright 2024. All Rights Reserved by MedPath